Poly

Plantronics, Inc. (“Poly” – formerly Plantronics and Polycom) (NYSE: PLT) is a global communications company that powers meaningful human connection and collaboration. Poly combines legendary audio expertise and powerful video and conferencing capabilities to overcome the distractions, complexity, and distance that make communication in and out of the workplace challenging. Poly believes in solutions that make life easier when they work together and with our partner’s services. Our headsets, software, desk phones, audio and video conferencing, analytics and services are used worldwide and are a leading choice for every kind of workspace.

C-Suite On Deck

Amy Barzdukas, EVP and Chief Marketing Officer at Poly is a marketing and communications leader with extensive experience in setting strategy, shifting perceptions, advising customers, digital marketing, revenue marketing, integrated marketing communications, and public relations i...

Events

Related News

POLYMERASE CHAIN REACTION (PCR) MARKET - GLOBAL INDUSTRY ANALYSIS 2014 - 2020

Open PR | December 28, 2016

news image

Although, the use of PCR has been mostly confined to research institutions, pharmaceutical and biotechnology industries, currently, the market has seen an increasing preference of PCR in the commercial diagnostic laboratories and hospitals due to precise diagnoses of life-threatening diseases such as cancer and Ebola. Multi-chain diagnostic laboratories are currently focusing on expanding their operations in less developed areas by acquiring standalone laboratories with minimal infrastructure. T...

Read More

ACTIVISTS CRY FOUL OVER NEW HIV DRUG MONOPOLY

The Economic Times | January 27, 2017

news image

Doctors and aid organisations have called upon the Competition Commission of India and the price regulator to step in to ward off the monopoly over a new HIV drug, dolutegravir, which received the approval of the Indian drug controller last month....

Read More

GILEAD SHELVED SAFER HIV DRUGS FOR YEARS TO PROTECT ITS TDF MONOPOLY, ANOTHER LAWSUIT SAYS

fiercepharma | May 09, 2018

news image

Gilead Sciences is no stranger to furious patients and advocates, many of whom have said over the years that the company puts shareholder interests over their own. Now, two patients allege that the drugmaker shelved better HIV treatments in favor of monopoly sales and at the detriment of their health. Gilead's Viread, or tenofovir disoproxil fumarate (TDF), won FDA approval in 2001. The plaintiffs, California residents Michael Lujano and Jonathan Gary, allege that the company knew the compou...

Read More

NEW METHOD MEASURES 3-D POLYMER PROCESSING PRECISELY

Phys.org | October 09, 2018

news image

Recipes for three-dimensional (3-D) printing, or additive manufacturing, of parts, have required as much guesswork as science. Until now. Resins and other materials that react under light to form polymers, or long chains of molecules, are attractive for 3-D printing of parts ranging from architectural models to functioning human organs. But it's been a mystery what happens to the materials' mechanical and flow properties during the curing process at the scale of a single voxel. A voxel i...

Read More
news image

POLYMERASE CHAIN REACTION (PCR) MARKET - GLOBAL INDUSTRY ANALYSIS 2014 - 2020

Open PR | December 28, 2016

Although, the use of PCR has been mostly confined to research institutions, pharmaceutical and biotechnology industries, currently, the market has seen an increasing preference of PCR in the commercial diagnostic laboratories and hospitals due to precise diagnoses of life-threatening diseases such as cancer and Ebola. Multi-chain diagnostic laboratories are currently focusing on expanding their operations in less developed areas by acquiring standalone laboratories with minimal infrastructure. T...

Read More
news image

ACTIVISTS CRY FOUL OVER NEW HIV DRUG MONOPOLY

The Economic Times | January 27, 2017

Doctors and aid organisations have called upon the Competition Commission of India and the price regulator to step in to ward off the monopoly over a new HIV drug, dolutegravir, which received the approval of the Indian drug controller last month....

Read More
news image

GILEAD SHELVED SAFER HIV DRUGS FOR YEARS TO PROTECT ITS TDF MONOPOLY, ANOTHER LAWSUIT SAYS

fiercepharma | May 09, 2018

Gilead Sciences is no stranger to furious patients and advocates, many of whom have said over the years that the company puts shareholder interests over their own. Now, two patients allege that the drugmaker shelved better HIV treatments in favor of monopoly sales and at the detriment of their health. Gilead's Viread, or tenofovir disoproxil fumarate (TDF), won FDA approval in 2001. The plaintiffs, California residents Michael Lujano and Jonathan Gary, allege that the company knew the compou...

Read More
news image

NEW METHOD MEASURES 3-D POLYMER PROCESSING PRECISELY

Phys.org | October 09, 2018

Recipes for three-dimensional (3-D) printing, or additive manufacturing, of parts, have required as much guesswork as science. Until now. Resins and other materials that react under light to form polymers, or long chains of molecules, are attractive for 3-D printing of parts ranging from architectural models to functioning human organs. But it's been a mystery what happens to the materials' mechanical and flow properties during the curing process at the scale of a single voxel. A voxel i...

Read More